Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease. 
Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization [WHO] grade 3 or 4) 
Life expectancy â‰¥ 3 months 
